Abstract 2058P
Background
Strategies targeting oral anticancer drug (OAD) waste are required to improve sustainability and affordability of these expensive treatments frequently remaining unused by patients. This study aims to quantify waste reduction, cost-savings and environmental impact obtained by redispensing unused OADs compared to standard practice of disposal.
Methods
A prospective, single-arm intervention study was conducted in four Dutch hospitals. Eligible patients were ≥18 years, diagnosed with cancer and prescribed an OAD. During twelve months, participants received OAD packages sealed with a time-temperature indicator. If unused, OADs were returned to the pharmacy where quality was assured by checking authenticity, shelf life and storage temperature. OADs of verified quality were redispensed to other patients. Waste reduction was expressed as the percentage returned OADs that were redispensed. Mean annual cost-savings per patient were costs of redispensed OADs minus operational expenses from a healthcare perspective. Impact on environmental indicators was assessed via a cradle-to-grave Life Cycle Assessment. Patient subgroups associated with positive cost-savings were identified with multiple logistic regression. Scenarios analyses on the effect of optimized quality assurance and patient population selection was performed.
Results
1,071 patients participated, median age 70 years (IQR: 62–75) and 41.9% female. 224 OAD packages (1.7%) of 128 patients (12.0%) were redispensed (2.4% of total drug costs), reducing waste by 68.1% and providing mean annual cost-savings of €576 per patient (95% CI: 444–709). Optimizing quality assurance and targeting patient subgroups (< 24 months OAD use/using targeted therapies) could increase mean annual cost-savings up to €1,348 (1,039 – 1,697) per patient. Waste reduction was associated with mean annual environmental benefits of >1 kg CO2 per patient, but only with an optimized quality assurance procedure a net beneficial impact on environmental indicators was achieved.
Conclusions
Redispensing unused OADs reduces waste substantially, generates cost-savings and can benefit environmental impact, improving sustainability and affordability of cancer treatment.
Clinical trial identification
WHO International Clinical Trials Registry Platform (ICTRP) Identifier: NL9208.
Editorial acknowledgement
Legal entity responsible for the study
ROAD-study group.
Funding
Netherlands Organisation for Health Research and Development ZonMw (grant 848018008).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06